Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $3.87 in the prior trading day, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $4.01, up 3.62%. In other words, the price has increased by $3.62 from its previous closing price. On the day, 1.08 million shares were traded. ABCL stock price reached its highest trading level at $4.01 during the session, while it also had its lowest trading level at $3.83.
Ratios:
Our goal is to gain a better understanding of ABCL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 26 ’23 when Thermopylae Holdings Ltd. bought 153,000 shares for $6.52 per share. The transaction valued at 997,728 led to the insider holds 56,012,493 shares of the business.
Booth Andrew bought 14,500 shares of ABCL for $99,325 on May 26 ’23. The Chief Financial Officer now owns 153,000 shares after completing the transaction at $6.85 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1174055936 and an Enterprise Value of 490851424. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.87 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 12.909 whereas that against EBITDA is -2.307.
Stock Price History:
The Beta on a monthly basis for ABCL is 0.39, which has changed by -0.4041605 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, ABCL has reached a high of $8.05, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -14.85%, while the 200-Day Moving Average is calculated to be -22.71%.
Shares Statistics:
The stock has traded on average 1.32M shares per day over the past 3-months and 1091190 shares per day over the last 10 days, according to various share statistics. A total of 290.82M shares are outstanding, with a floating share count of 205.17M. Insiders hold about 29.92% of the company’s shares, while institutions hold 38.40% stake in the company. Shares short for ABCL as of 1711584000 were 23590860 with a Short Ratio of 17.82, compared to 1709164800 on 22784725. Therefore, it implies a Short% of Shares Outstanding of 23590860 and a Short% of Float of 11.18.
Earnings Estimates
AbCellera Biologics Inc (ABCL) is presently subject to a detailed evaluation by 8 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of $-0.16 for the current quarter, with a high estimate of $-0.12 and a low estimate of $-0.25, while EPS last year was $-0.14. The consensus estimate for the next quarter is $-0.15, with high estimates of $-0.1 and low estimates of $-0.25.
Analysts are recommending an EPS of between $-0.48 and $-1.01 for the fiscal current year, implying an average EPS of $-0.64. EPS for the following year is $-0.69, with 6 analysts recommending between $-0.45 and $-0.99.
Revenue Estimates
8 analysts predict $11.02M in revenue for the current quarter. It ranges from a high estimate of $18.29M to a low estimate of $8.9M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $12.19M, an estimated decrease of -9.60% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $11.53M, an increase of 14.70% over than the figure of $-9.60% in the same quarter last year. There is a high estimate of $17.36M for the next quarter, whereas the lowest estimate is $9.22M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $77.46M, while the lowest revenue estimate was $36.9M, resulting in an average revenue estimate of $47.83M. In the same quarter a year ago, actual revenue was $38.02M, up 25.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $68.42M in the next fiscal year. The high estimate is $117.86M and the low estimate is $46.4M. The average revenue growth estimate for next year is up 43.00% from the average revenue estimate for this year.
